Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 5/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | C1S | P09871 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31280556 | 1.00 | KHK (0.48) | KHKCCR1MAP4K1P2RY12C1S | |
| SCHEMBL23711736 | 0.88 | KHK (0.49) | KHKCCR1MAP4K1P2RY12CA12 | |
| SCHEMBL31279546 | 0.88 | KHK (0.49) | KHKCCR1MAP4K1P2RY12CA12 | |
| SCHEMBL23734200 | 0.82 | GPR119 (0.59) | KHKMAPTLMNA | |
| SCHEMBL31279608 | 0.81 | KHK (0.61) | KHKMAPTLMNAALDH1A1 | |
| SCHEMBL23711746 | 0.81 | KHK (0.61) | KHKMAPTLMNAALDH1A1 | |
| SCHEMBL31280064 | 0.78 | KHK (0.52) | KHKMAP4K1C1SMAPTALDH1A1 | |
| SCHEMBL23711778 | 0.78 | KHK (0.52) | KHKMAP4K1C1SMAPTALDH1A1 | |
| SCHEMBL23711751 | 0.78 | ADRB1 (0.63) | KHKMAP4K1MAPTALDH1A1RAB9A | |
| SCHEMBL31278709 | 0.78 | ADRB1 (0.63) | KHKMAP4K1MAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210275494-A1 | METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-09-09 | — | — | US | disclosed |
| US-20210275494-A1 | METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-09-09 | — | — | US | disclosed |
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-08-10 | — | — | US | disclosed |
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275494-A1 | METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE | KHK, GCK, FN3K | KHK 1/4885CCR1 1784/4885MAP4K1 74/4885 |
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | KHK, GCK, HK1 | KHK 1/4885CCR1 3944/4885MAP4K1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.